ReviewTherapeutic advances in psychopharmacology2019
Psychotic disorders in late life: a narrative review.
Review in Therapeutic advances in psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Rapid Resolution of Apophenic Psychosis With Low-Dose Olanzapine in Very Late-Onset Schizophrenia-Like Psychosis.Cureus · 2026Article
- Schizophrenia-related suicide mortality in the United States by sex, 1999-2023.Discover mental health · 2026Article
- The Utility of Addenbrooke's Cognitive Examination III (ACE-III) in Differentiating Neurodegenerative Disorders with Psychotic Symptoms: A Narrative Review.Healthcare (Basel, Switzerland) · 2026Review
- Understanding barriers to receiving psychological intervention for older persons who experience hallucinations.BMC geriatrics · 2026Article
- Risk Factors for Late-Onset Psychosis: A Case-Control Study.Schizophrenia bulletin · 2025Article
- Auditory Hallucinations as the First Symptom of Alzheimer´s Disease - A Case Report.Current Alzheimer research · 2025Article
- Subsyndromes and symptom clusters: Multilevel factor analysis of behavioral and psychological symptoms of dementia with intensive longitudinal data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Medication Dosage Impact on Mortality in Old-Age Individuals with Schizophrenia: A National Cohort Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Serum Interleukin-6 in Schizophrenia: Associations with Clinical and Sociodemographic Characteristics.Consortium psychiatricum · 2023Article
- Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HTNeurology. Clinical practice · 2023Article
- Military veterans and civilians' mental health diagnoses: an analysis of secondary mental health services.Social psychiatry and psychiatric epidemiology · 2023Article
- Late onset psychosis treatment with adjunctive medicines.Frontiers in psychiatry · 2023Article
- Article
- Magical thinking in individuals with high polygenic risk for schizophrenia but no non-affective psychoses-a general population study.Molecular psychiatry · 2022Article
- Delusional Disorder in Old Age: A Hypothesis-Driven Review of Recent Work Focusing on Epidemiology, Clinical Aspects, and Outcomes.International journal of environmental research and public health · 2022Review
- Clinical Approaches to Late-Onset Psychosis.Journal of personalized medicine · 2022Review
- Factors associated with late-life psychosis in primary care older adults without a diagnosis of dementia.Social psychiatry and psychiatric epidemiology · 2022Article
- Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychotic disorders are not uncommon in late life. These disorders often have varied etiologies, different clinical presentations, and are associated with significant morbidity and mortality among the older adult population. Psychotic disorders in late life develop due to the complex interaction between various biological, psychological, social, and environmental factors. Given the significant morbidity and mortality associated with psychotic disorders in late life, a comprehensive work-up should be conducted when they are encountered. The assessment should not only identify the potential etiologies for the psychotic disorders, but also recognize factors that predicts possible outcomes for these disorders. Treatment approaches for psychotic disorders in late life should include a combination of nonpharmacological management strategies with the judicious use of psychotropic medications. When antipsychotic medications are necessary, they should be used cautiously with the goal of optimizing outcomes with regular monitoring of their efficacy and adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.